Markets:

Overview

News

Currencies

International

Treasuries

Blueprint Medicines Corporation - Common Stock (NQ:BPMC)

129.46 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 17, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Blueprint Medicines Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar

April 06, 2026

Shares of Soleno Therapeutics (NASDAQ: SLNO) surged more than 32% in early trading on Monday, April 6, 2026, following the blockbuster announcement that Neurocrine Biosciences (NASDAQ: NBIX) has...

Via MarketMinute

Topics Intellectual Property

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Analyst Expectations For Blueprint Medicines's Future ↗

June 02, 2025

Via Benzinga

Cogent Biosciences Soars to 52-Week High on "Breakthrough" Systemic Mastocytosis Trial Results

October 13, 2025

Cogent Biosciences (NASDAQ: COGT) experienced a dramatic surge in its stock price, hitting a 52-week high in early July 2025, following the announcement of highly positive "breakthrough results" from...

Via MarketMinute

Topics Economy Supply Chain

Shareholder Alert: The Ademi Firm Continues to Investigate the Blueprint Medicines Corporation Transaction

September 15, 2025

From Ademi & Fruchter LLP

Via Business Wire

Shareholder Alert: The Ademi Firm Investigates the Blueprint Medicines Corporation Transaction

August 27, 2025

From Ademi & Fruchter LLP

Via Business Wire

Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy ↗

July 22, 2025

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Via Benzinga

What's Driving the Market Sentiment Around Blueprint Medicines? ↗

July 14, 2025

Via Benzinga

Cogent's Chronic Immune Disorder Drug Has Strong Potential To Become A Blockbuster: Analyst ↗

July 08, 2025

Cogent's bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.

Via Benzinga

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC

June 20, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

June 17, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, SVT, SSBK on Behalf of Shareholders

June 15, 2025

From Halper Sadeh LLC

Via GlobeNewswire

Unusual volume stocks are being observed in Monday's session. ↗

June 09, 2025

Unusual volume stocks in Monday's session

Via Chartmill

Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio? ↗

June 08, 2025

Via Benzinga

Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta ↗

June 06, 2025

Byron Allen dials out, Salesforce logs in. Here are the various deal announcements of the past week plus bankruptcy updates.

Via Benzinga

Topics Bankruptcy

This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday ↗

June 04, 2025

Via Benzinga

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VIGL, STR, BPMC, STRM on Behalf of Shareholders

June 04, 2025

From Halper Sadeh LLC

Via GlobeNewswire

June 03, 2025

From Kahn Swick & Foti, LLC

Via Business Wire

This ASML Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

June 03, 2025

Via Benzinga

This Salesforce Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗

June 03, 2025

Via Benzinga

Market Monitor News June 03 (Cleveland-Cliffs, Blueprint Medicines UP - First Solar DOWN) ↗

June 03, 2025

Wall Street Climbs Despite Trade Tensions: Steel Stocks Shine, Apple Impresses

Via Chartmill

Blueprint Medicines Stock Lands Several Downgrades After Sanofi’s Buyout Deal, But Retail Bulls Keep The Faith ↗

June 02, 2025

Analysts revised price targets near the deal’s $129-per-share valuation.

Via Stocktwits

Topics Government

Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday ↗

June 02, 2025

Via Benzinga

Which stocks are gapping on Monday? ↗

June 02, 2025

Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Boeing To Rally More Than 25%? Here Are 10 Top Analyst Forecasts For Monday ↗

June 02, 2025

Via Benzinga

This Union Pacific Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

June 02, 2025

Via Benzinga

Sanofi To Buy Blueprint Medicines For Up To $9.5B: Retail Sees More Acquisition Offers From European Pharma Companies ↗

June 02, 2025

Sanofi will pay $129 per share in cash at closing, representing a 27% premium to Blueprint’s closing price on Friday of $101.35.

Via Stocktwits

These stocks that are showing activity before the opening bell on Monday. ↗

June 02, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders

June 02, 2025

From Ademi & Fruchter LLP

Via Business Wire

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout ↗

June 02, 2025

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.